Nuveen LLC Buys Shares of 4,714,861 ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Nuveen LLC has acquired a new position in ADMA Biologics Inc, purchasing 4,714,861 shares valued at approximately $93.5 million, representing about 1.98% of the company.
• ADMA Biologics reported earnings per share (EPS) of $0.15 in its latest quarterly earnings, surpassing analysts' expectations of $0.14, with revenues of $121.98 million, up 13.8% year-over-year.
• Insider transactions included significant stock sales by directors Jerrold B. Grossman and Steve Elms, with a total of approximately 464,621 shares sold worth about $9.64 million over the last quarter.

Nuveen LLC bought a new stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,714,861 shares of the biotechnology company's stock, valued at approximately $93,543,000. Nuveen LLC owned approximately 1.98% of ADMA Biologics at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of ADMA Biologics in the 1st quarter worth $35,000. Tsfg LLC acquired a new position in shares of ADMA Biologics during the first quarter worth about $51,000. Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics during the first quarter worth about $52,000. Farther Finance Advisors LLC increased its stake in shares of ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 2,505 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in shares of ADMA Biologics during the fourth quarter worth about $85,000. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA traded up $0.02 during trading hours on Friday, reaching $16.99. The company had a trading volume of 3,108,545 shares, compared to its average volume of 3,534,720. The firm has a 50 day simple moving average of $18.29 and a 200-day simple moving average of $18.85. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of 19.76 and a beta of 0.38. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business's revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.13 EPS. Research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ADMA. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial boosted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th.

Insider Activity

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares in the company, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director owned 478,194 shares of the company's stock, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock worth $9,644,269 in the last 90 days. 3.50% of the stock is currently owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.